Currently, every HER2‐positive BC patient is eligible for anti‐HER2 therapy regardless of HER2‐E status; yet, the response rate varies, with 20% of patients experiencing recurrence and metastasis post‐adjuvant therapy [29, 30]. This evidence concerns the gene ERBB2 and breast cancer.